地西他滨联合预激方案治疗中高危骨髓增生异常综合征及急性髓系白血病20例分析

Analyse Decitabine Combined with CAG/HAG to Treat 20 Patients with Medium and High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

目的探究地西他滨联合预激方案治疗中高危骨髓增生异常综合征及急性髓系白血病的临床价值。方法方便选取并分析2012年8月—2015年8月该院收治的用地西他滨联合预激方案治疗的20例中高危MDS和AML患者,观察其临床疗效及安全性。结果 8例患者为CR,6例PR,在此其中2例经两个疗程治疗后完全缓解,6例NR。总有效率70%,l疗程完全缓解率40%。Ⅳ度骨髓抑制100%,缓解患者化疗后血小板恢复正常时间17-23 d,白细胞恢复正常时间较血小板晚,平均25 d左右。结论对于急性髓系白血病/骨髓增生异常综合症患者,使用地西他宾治疗可以取得满意效果。风险可控,老年人也能耐受,但有不良预后的染色体或突变基因的患者效果不佳。

Objective To explore the clinical value of the combination of decitabine and CAG/HAG in the treatment of high risk patients with myelodysplastic syndrome and acute myeloid leukemia. Methods Convenient selection and analyse the clinical efficacy and safety of 20 patients with medium /high risk MDS and AML that were treated with the combination of decitabine and CAG/HAG in our department from August 2012 to August 2015. Results 8 cases of CR, 6 cases of PR, in which 2 cases after two courses of treatment complete remission, 6 cases of NR. The total effective rate was 70%,and the complete remission rate was 40% in 1 treatment course. IV degree of bone marrow suppression 100%, remission of patients with chemotherapy after the normal time of platelet recovery 17-23 d, the white blood cells to restore normal time compared with platelets, the average 25 days or so. Conclusion in patients with acute myeloid leukemia / myelodysplastic syndrome, the use of the treatment of the decitabine can achieve satisfactory results. Risk control, the elderly are also able to tolerate, but patients with poor chromosomal or mutant gene have poor prognosis.